Connect with us

Press Release

“Algorithm + Credit” Rebuild the Value Foundation of DeFi

Published

on

DeFi still has higher attention, with rapid technological innovation and continuous expansion of application scope, The goal of DeFi is undoubtedly to build a more effective, free, and transparent financial ecology. However, finance always develops with money and brings value exchange. Therefore, whether it is a decentralized scenario or a mass application toward reality in the future, stable cryptocurrency is crucial for users, so as to realize the dream of making virtual ideas become reality.

For this reason, in the field of cryptocurrency, many teams have been exploring stable currency. According to CryptoQuant data, stabilecoin holdings on global crypto exchanges hit a high record of $9.8 billion as of March 28, 2021. At the same time, the total stable currency market capitalization once topped $80 billion, according to CoinGecko, the current daily trading volume of all stable currencies is about $118.340 billion. Also, CoinMarketCap shows there are 16 mainstream stable currencies now.

The stable currency is illusory?

In general, both USDT and DAI are still on their way and haven’t really achieved the goal of “stable currency”. Tether’s White Paper said: “Tether is a decentralized cryptocurrency, but we are not a perfectly decentralized company. We store all of our assets as a centralized pledge.” Therefore, USDT is just borrowing the name of the cryptocurrency, but it is not really decentralized.

DAI, developed by MakerDao, is the largest decentralized stable currency on Ethereum. It is issued with the guarantee of the full amount of assets on the blockchain. It is only generated in the application scenario based on the mortgage, and the market value of the mortgage assets is the ceiling of it. Therefore, these stable currencies are illusory in a sense.

Will algorithmic stable currencies finally fail?

Now let’s take a look at the development process of algorithmic stable currencies, known as the holy grail of cryptocurrency. From stable currency1.0 represented by AMPL, stable currency2.0 represented by Basis Cash to stable currency 3.0: Frax Finance, all of them have gone through a period of growth. However, the stable currency reality is that we live under the sense of “ever-changing”, and stable value is still in the ideal.

AMPL algorithmic stable currency is used to increase or decrease the supply of AMPL in order to keep the price of AMPL around $ 1. Ampleforth uses Rebase operation to change the AMPL held by all users as a whole. The Rebase price is based on the average price of the past 24 hours. When this price is above $1.05, the AMPL balance in all users’ wallets increases simultaneously. At prices below $0.95, all users’ AMPL balances decrease simultaneously. During this process, the percentage of AMPL held by users in the supply does not change. It looks like everything is fine on its own, but when the price of cryptos falls to the point where deflation is needed, both the quantity and price of coins held by users are falling, so users face a double whammy.

So it’s easy to create a death spiral. Similarly, when crypto price rises, it is easy to create an upward death spiral. Thus it can be seen that this price model only has two possibilities: the price continues to fall, get into the infinite death circle and leave the market, and the price rises steadily to around 1USDT; Prices rising, the AMPL has been printing (dividend), AMPL reserve disappeared, crypto began to value return, people in loss cannot gain AMPL, prices will fall back near 1 USDT (need funds continue getting into the market), so it is difficult to see AMPL achieve speculation, meanwhile achieve stability, And stability is a necessary condition for a stable currency.

Basis Cash, as represented by 2.0, includes three tokens, Basis Cash (BAC), Basis Share (BAS), and Basis Bond (BAB), among which BAB is non-transferable. The BAC is the stable currency, anchored to $1; BAS is an equity token, and newly-minted BAC tokens can be allocated. BAB is a bond. There is nothing wrong with Basis Cash based on the algorithm itself, but without a good application scenario, relying on the debt market itself is dangerous. There is actually a problem with debt financing in traditional markets, where those “too big to fail” entities can take on the risk of impunity through socialized bailout costs. It is entirely possible that Basis Cash could go into a debt spiral, in which case there would be no willing contributors, the debt would accumulate and the protocol would collapse.

Finance FX is the first partial algorithmic stable currency project, adding the concept of using “partially stable” as a collateral asset to the existing algorithmic stable currency. There are two types of tokens in Frax, the stabilization token Frax, and the governance token FXS. Frax costs USDC and FXS, but only USDC during creation. The initial mortgage rate is 100%, that is, all USDC mortgage is used to cast FRAX. After that, the mortgage rate will be adjusted every hour. If the price of FRAX is more than $1, the mortgage rate will be reduced and FXS ‘share in it will be increased. Raise the mortgage rate if the Frax falls below $1. The mortgage rate is adjusted every hour by 0.25% each time. But its high mortgage ratio leads to the lack of user appeal, its currency numbers and market supply have been stagnant.

Although the above three generations of stable currencies seem to be making breakthroughs and innovations, they do not give a satisfactory answer on how to solve the credit problem. However, algorithm stable currency that cannot solve the credit problem is useless. Bitcoin came into being to solve the problem of credit, but the stable currency, as an important extension of its development, has not inherited the legacy of credit, and is still stuck in the algorithm.

Crypto Credit Network (CCN)

In the financial field, credit is the foundation and the lifeblood. This is true of both traditional and modern financial systems. In the traditional financial system, credit mainly relies on the guarantee of laws and institutions. Apart from the high operation cost, the “credit crisis” gradually exposed by financial intermediaries is the fundamental reason why people urgently embrace the blockchain technology. Algorithm stable currency is going to help cryptos solve the credit problems, guaranteeing machine credit by algorithm, which does not rely on third-party subjective will and makes transaction transparent, efficient, reliable, and stable, let people who do not have to establish credit relationship between each other to achieve cooperation and free trading, reduce the cost of credit.

However, the world of blockchain cryptocurrency is a chaotic existence without a role name. To change from chaos to brightness, each individual needs to have his or her own identity, so that we can obtain the faith like phoenix nirvana. The CCN gives each individual a unique CID (Crypto Identification), which is the most basic rule in the Crypto world. To build a new crypto world of order, autonomy, and equality.

The construction of CCN not only takes blockchain technology as support, but also has a reasonable economic incentive mechanism. Reasonable use of incentive mechanism is an effective means to stimulate all parties to participate in the construction of CCN.

A sound incentive mechanism, reasonable mechanism design from the perspective of leading efficiency and fair governance, can make the value generated by credit information flow effectively to the value provider in the blockchain world, punish the evil behavior, and resolve the conflict between individual interests and collective interests. It makes the individual’s behavior of pursuing individual interests unified with the goal of maximizing collective value.

Therefore, CCN can further clarify the economic interests of each participant and the overall interests of the network, so as to fully mobilize the enthusiasm of each participant and guarantee great development of CCN from the source.

The CCN consists of three different identities: Creator, Guardian, and Angel, all of them have established screening mechanisms. Only firm believers can obtain the CCN identity. Early believers are required to contribute to maintaining the stability of early CCN by burning GAC tokens. Therefore, they are not only holders of GaeaCoin, but also determined preachers and builders. When GaeaCoin issues additional shares, it will also receive a corresponding percentage of GAC tokens as a reward.

The establishment of this system aims to provide every GaeaCoin participant with the opportunity to contribute to the community construction, and to create a healthy crypto community culture of dedication and autonomy through consensus, symbiosis, co-construction, and sharing.

In CCN, although the identity is different, the residents on the chain of CCN build the initial transaction link according to their CID address, and constantly expand CCN on the chain. Open CID needs to be recommended by the network resident, once the link is formed, it cannot be changed forever. Each of the three different identities requires a different number of GAC tokens to burn, which can be viewed on the GaeaCoin network. GaeaCoin network residents have different rights according to their status.

The integration with the DEX: OxySwap has pioneered a full range of applications

There is a natural interdependence between exchange and stable currency. The exchange has always been an important part of crypto digital asset market, and it is also the first application place of stable currency. Like Binance with BUSD and Huobi with HUSD, OKEx also launched USDK on June 3, 2019. Traditional CEXs are fiat currencies, where fiat currencies are exchanged for cryptos. If you want to buy crypto digital assets, you need to top up fiat currency, which undoubtedly increases the economic and time costs of investors in the process of exchange. The emergence of a stable currency can not only solve the above problems but also effectively avoid legal risks in the process of the transaction.

As it should be, the integration of GaeaCoin ecology and OxySwap not only lay a solid foundation for stable currency: GAC token application, but also creates opportunities for it to open up more and wider application scenarios.

OxySwap is a decentralized exchange running on the BSC with a collection of DEX liquidity mining, which offers functions of exchange, liquidity, market making, and so on. The strength of OxySwap guarantees the usages of the stable currency: GAC.

GAC will lead a brighter way

GaeaCoin algorithm stable currency: GAC dares to face the challenge, according to the industry news, GAC praises is not only relatively stable from the concept, but also to really put into application. In addition to GAC (GaeaCoin), GaeaCoin ecology also includes GAB (GaeaCoin Bond) and GASH (GaeaCoin Share), which serve to maintain the stability of GAC. GaeaCoin Ecology also integrates GaeaCoin protocol, algorithm, robustness, price response, encryption, and other technologies, superposed with the DeFi ecology of Crypto Credit Network (CCN), OxySwap (DEX), and so on, providing a realistic solution for GAC, and leads it to move towards the real “stability”.

The integration of CCN and OxySwap points out the direction for the application of algorithmic stable currency. In fact, we can already feel the power of the GaeaCoin algorithm stable currency, and once it is used at a large scale, the ideal stable currency is expected to arrive ahead of time. DeFi will also build on this basis, using currency, lending, spot trading, and other components to build continuously upgraded Lego of DeFi.

GaeaCoin’s move directly challenges the world’s centralized stable currency giants such as USDT and USDC, but compared to the previous challenges of AMPL, BAC, and FRAX, this well-prepared challenge looks more anticipated!

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

AI Labs leverages Google’s Gemini AI to bring market analysis into its Chatbot

Published

on

Singapore – 19/11/2026 – (SeaPRwire) – AI Labs chatbot, AIV, combines crypto and equity market analysis with trading strategies and risk assessments, as it reports about 700,000 active users, daily trading volumes of US$50-100M a day, and total value locked (TVL) of $80-100M across its platform.

AI Labs is using Google‘s Gemini artificial intelligence technology to power its AIV Chatbot, enabling users to explore cryptocurrency and equity markets through conversational analysis, trading scenarios and investment risk assessments.

The chatbot goes beyond conventional price summaries by incorporating technical indicators, business fundamentals, institutional sentiment and market catalysts. It can also outline potential entry and exit levels, evaluate alternative trading strategies and identify risks that could undermine an investment thesis.

“Our aim is to help users understand not just a market view, but the reasoning and risks behind it,“ said Ryan Chi, founder and chief executive officer of AI Labs. “AIV brings those elements into a conversation, so users can explore different scenarios rather than rely on a standalone buy or sell signal.“

Examples provided by the company demonstrate the chatbot‘s capabilities across multiple assets. A Bitcoin query generates a seven-day trading scenario incorporating technical support levels, ETF flows and downside risks. An Nvidia analysis combines technical indicators with growth prospects, valuation and earnings volatility, while a Solana example explores long-short strategies and liquidation risks.

“The important distinction is between generating a trading idea and explaining the assumptions and risks behind it,“ said Terry Tan, an advisor to AI Labs. “AI-powered tools should support independent judgment by helping users understand both opportunities and potential downside scenarios.“

The company says it is continuing to onboard new users and is committed to making every reasonable effort to sustain the high levels of trading activity at US$50-100M daily as it expands its AI-powered financial services.

Media Contact

Company: AI Labs

Contact: Media Team

Email: ryan@academic-labs.org

Website: https://ai-labs.live/

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

China Medical System’s Innovative Oral Drug for Vitiligo, Povorcitinib Enrolls First Patient in China Phase III Clinical Trial

Published

on

SHENZHEN, CHINA – China Medical System Holdings Limited (“CMS” or the “Group”, 867.HK/8A8.SG) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited), has enrolled the first patient in the China Phase III clinical trial of its innovative oral JAK1 inhibitor Povorcitinib Phosphate Tablets (“povorcitinib” or the “Product”) for the treatment of vitiligo on 19 November 2026.

 

The trial is a multi-center, randomized, double-blind, placebo-controlled Phase III clinical study evaluating the efficacy and safety of povorcitinib in Chinese adult patients with non-segmental vitiligo. Led by Professor Li Chunying of the First Affiliated Hospital of Air Force Medical University, the study is planned to be conducted at approximately 44 clinical research centers across China and is expected to enroll approximately 174 patients with non-segmental vitiligo.

 

The Product has previously completed a series of clinical trials related to pharmacokinetics and bioequivalence in healthy participants in China, and has been included in the list of Breakthrough Therapeutic Drugs by the Center for Drug Evaluation of the National Medical Products Administration of the People’s Republic of China (“NMPA”). This certification has the potential to accelerate its development and review process. The enrollment of the first patient in this China Phase III clinical trial marks a pivotal stage in the Product’s clinical development in China and lays a foundation for further evaluating its efficacy and safety in Chinese patients with vitiligo.

 

Addressing Unmet Clinical Needs in Vitiligo with Novel and Differentiated Treatment Options

Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin. It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million[1]. Currently, treatment options are limited for vitiligo patients who require systemic therapy, and their clinical treatment needs remain inadequately met.

 

Overactivity of certain proinflammatory cytokines that signal through the JAK-STAT pathway, is believed to drive inflammation and contribute to the pathogenesis and progression of vitiligo. Incyte has announced that Phase III clinical studies outside China of the oral JAK1 inhibitor Povorcitinib Phosphate Tablets in adults with non-segmental vitiligo have met the primary endpoints[2]. If approved in China, the Product has the potential to provide a new oral treatment option for patients with non-segmental vitiligo and, together with Dermavon’s commercialized innovative drug Lumirix® (ruxolitinib phosphate cream), provide vitiligo patients with comprehensive and diversified treatment options, from precise topical intervention to systemic treatment.

 

Focusing on major skin diseases such as vitiligo, atopic dermatitis and psoriasis, Dermavon has developed an innovative product portfolio covering different disease stages and clinical needs. The enrollment of the first patient in the Phase III clinical trial of povorcitinib in China represents another important milestone in Dermavon’s advancement of local clinical development for global innovative drugs. Going forward, Dermavon will continue to leverage its strong global R&D partnerships and clinical development capabilities in China to accelerate the translation of innovation into clinical application and bring more professional and differentiated treatment options to patients with skin diseases in China.

 

More Information About Povorcitinib Phosphate Tablets

Povorcitinib is a selective oral small-molecule JAK1 inhibitor, with compound and use patents in certain countries/regions in the Territory. In addition to vitiligo, the Product has also demonstrated development potential in other indications. Incyte is conducting Phase III clinical trials of povorcitinib for the treatment of prurigo nodularis (PN) in several countries outside China, and has obtained European Commission approval for hidradenitis suppurativa (HS). Dermavon may also consider initiating clinical development of the Product in China for the treatment of additional skin-related diseases.

 

A subsidiary of Dermavon entered into a Collaboration and License Agreement (the “License Agreement”) for povorcitinib on 31 March 2024 with Incyte, obtaining an exclusive license to research, develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights of povorcitinib in the Territory other than Mainland China to China Medical System Holdings Limited (excluding Dermavon and its subsidiaries).

 

 

About CMS

CMS is an innovative pharmaceutical company focused on the identification, building, and full lifecycle management of differentiated specialty pharmaceuticals. With a dual-engine approach of in-house R&D and collaborative R&D, and leveraging its core capability to build markets and brands from the ground up, the Group enables each medicine to fully realize both its clinical value and commercial value.

 

CMS has established an end-to-end capability loop across the full product lifecycle—precisely identifying quality innovation targets, matching them with optimal development pathways, and efficiently advancing clinical development and registration; developing medical strategies aligned with clinical needs, and driving scaled clinical adoption through a professional academic promotion system and network.

 

CMS focuses on advantaged specialties including cardiovascular-kidney-metabolic, central nervous system, gastroenterology, ophthalmology, and skin health. Through professional academic promotion and academic resources across multiple disease areas, CMS has built sustainable scale advantages in specialties, with its skin health business becoming a leading player in its segment. Meanwhile, CMS continues to strengthen its international replication capabilities, validating the transferability of its business model in emerging markets such as Southeast Asia and the Middle East, and injecting long-term momentum for the Group’s high-quality, sustainable development.

 

 

Reference

1、China Insights Consultancy (CIC) report

2、Public information on the Incyte official website:https://investor.incyte.com/news-releases/news-release-details/incyte-reports-first-quarter-2026-financial-results-and-provides

 

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

 

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

 

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Email: ir@cms.net.cn

Website: https://web.cms.net.cn/en/home/

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

ONAR’s Largest Acquisition Closed With Two Days Left in Q3

Published

on

NYC, New York, November 19th, 2026, FinanceWire

ONAR Holding Corporation (OTCID: ONAR) acquired affiliate marketing firm Advertise Purple on September 29, two days before the books closed on its third quarter. That timing left shareholders with an unusual snapshot. ONAR recorded the obligations it took on to buy a business more than three times its size by revenue, while just two days of that business’s sales counted toward the $1.06 million ONAR reported for the quarter.

Had ONAR owned Advertise Purple throughout the quarter, the two businesses would have generated $4.44 million in revenue, according to unaudited figures in CEO Claude Zdanow’s stockholder letter. Over the first nine months of 2026, combined revenue would have totaled $13.52 million, compared with the $3.13 million ONAR reported. Those figures show the historical scale of the business ONAR bought. They exclude interest on the acquisition debt and assume no cost savings from bringing the companies together.

What Advertise Purple brings to ONAR

The first signs of integration are showing up in how the two businesses find customers. JUICE, an ONAR marketing agency, now handles Advertise Purple’s own marketing and has brought it new business, according to Zdanow. Advertise Purple’s sales team, in turn, sends leads to JUICE each month. Its core leadership team stayed on after the acquisition.

ONAR is also introducing its technology to Advertise Purple’s teams and clients, including Cortex, which helps marketers connect advertising activity with online and offline sales. The fourth quarter will give shareholders their first full reporting period to assess how the businesses perform under common ownership.

Why the Nasdaq application matters

ONAR’s reported nine-month revenue rose 68% year over year, and its operating loss narrowed 60%. The company still posted a $3.61 million net loss and used $590,000 in cash from operations. Interest accounted for nearly three-quarters of the net loss, according to ONAR, and most of that interest was noncash.

At September 30, ONAR had $37.7 million in total liabilities, up from $9.7 million at the start of the year. About $16.4 million represented acquisition payments due over time, including an earnout tied to Advertise Purple’s performance. ONAR ended the quarter with a $15.2 million working capital deficit and said its filings continue to identify substantial doubt about its ability to continue as a going concern.

That puts financial weight behind ONAR’s pursuit of a Nasdaq Capital Market listing. A qualifying national exchange listing would automatically convert $11 million in junior secured notes into preferred stock. Without a listing, those notes remain outstanding and mature in March 2028. ONAR has approved a 1-for-250 reverse stock split as part of its listing preparations. The split has yet to take effect, and Nasdaq approval remains uncertain.

For shareholders, the next operating milestone comes with ONAR’s annual report. It will include the first full quarter of Advertise Purple’s revenue and expenses under ONAR ownership, giving investors a clearer view of what the larger business earns and how much cash it uses.

About ONAR Holding Corporation

ONAR (pronounced “Honor”) is an AI-powered marketing platform. ONAR acquires and operates specialist marketing agencies serving middle-market and growth-stage brands across performance marketing, creative, and commerce, and runs them on shared proprietary technology designed to automate up to 70% of manual agency work. Its technology division, ONAR Labs, develops and houses that technology, including ONAR AI, a marketing intelligence platform deployed across the Company’s agencies; Retina AI, a predictive customer intelligence platform; and Cortex, an offline and online sales attribution platform.

Together, these products are designed to make the Company’s teams more productive and to shift agency work from billable hours toward measurable client results. ONAR continues to expand the platform through disciplined acquisitions, including JUICE, Scale Partner, and Advertise Purple.

Learn more at https://www.onar.com/

Contact

President
Craig Fischer
ValueCorp
cf@valuecorptrading.com

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST